Release Date: 2024-05-28
Risk Stratifi Cation of Non-Muscle Invasive Bladder Cancer
Ismail Ulus (Author)
Release Date: 2024-05-28
In this section, most widely used risk classification systems for recurrence and progression explained. As non-muscle invasive bladder cancer is recurrent and progressive disease, it is very important to risk stratify patients to guide treatment and follow-up. In seperate headlines formation and shortcomings of these classifications are highlighted.
Media Type
PDF
Buy from
Price may vary by retailers
| Work Type | Book Chapter |
|---|---|
| Published in | Current Management of Non-Muscle Invasive Bladder Cancer |
| First Page | 97 |
| Last Page | 107 |
| DOI | https://doi.org/10.69860/nobel.9786053359197.8 |
| ISBN | 978-605-335-919-7 (PDF) |
| Language | ENG |
| Page Count | 11 |
| Copyright Holder | Nobel Tıp Kitabevleri |
| License | https://nobelpub.com/publish-with-us/copyright-and-licensing |
Ismail Ulus (Author)
MD, Bagcilar Training and Research Hospital
https://orcid.org/0000-0002-2005-9734
3Ismail Ulus has been a part of Department of Urology of Bagcilar Training and Research Hospital, Istanbul as urology specialist for eight years. In this uro-oncology intensive clinic, he is particularly interested in the surgery and follow-up of bladder cancer patients. He has several national and international research articles, book chapters and oral presentations in the field of novel diagnostic and treatment strategies for bladder cancer.
1. O’Sullivan B, Brierley J, Byrd D, Bosman F, Kehoe S, Kossary C, Piñeros M, Van Eycken E, Weir HK, Gospodarowicz M. The TNM classification of malignant tumors-towards common understanding and reasonable expectations. Lancet Oncol. 2017 Jul;18(7):849-851.
2. van Rhijn BWG, Hentschel AE, Bründl J, Compérat EM, Hernández V, Čapoun O, et al.; Multi-center EAU Non-Muscle-Invasive Bladder Cancer Guidelines Panel Study Consortium on the WHO1973 WHO 2004 2016 Classification Systems for Grade. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol. 2021 Apr;4(2):182-191.
3. Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, et al.; European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021 Apr;79(4):480-488.
4. Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Sylvester RJ, Kamat AM. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. Eur Urol Oncol. 2022 Feb;5(1):84-91.
5. Shirakawa H, Kikuchi E, Tanaka N, Matsumoto K, Miyajima A, Nakamura S, Oya M. Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer. BJU Int. 2012 Sep;110(6 Pt B):E216-21.
6. Herr HW, Milan TN, Dalbagni G. BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. Urol Oncol. 2015 Mar;33(3):108.e1-4.
7. Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS, Chung J, Lee KH. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol. 2009 Dec;182(6):2625-30.
8. Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol. 2005 Jul;48(1):53-9.
9. Shapur NK, Katz R, Pode D, Shapiro A, Yutkin V, Pizov G, Appelbaum L, Zorn KC, Duvdevani M, Landau EH, Gofrit ON. Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare Tumors. 2011 Apr 4;3(2):e22.
10. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466- 5; discussion 475-7.
11. Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, de Reijke TM, Turkeri L, Collette S, Oddens J. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol. 2016 Jan;69(1):60-9.
12. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009 Nov;182(5):2195-203.
| onix_3.0::thoth | Thoth ONIX 3.0 |
|---|---|
| onix_3.0::project_muse | Project MUSE ONIX 3.0 |
| onix_3.0::oapen | OAPEN ONIX 3.0 |
| onix_3.0::jstor | JSTOR ONIX 3.0 |
| onix_3.0::google_books | Google Books ONIX 3.0 |
| onix_3.0::overdrive | OverDrive ONIX 3.0 |
| onix_2.1::ebsco_host | EBSCO Host ONIX 2.1 |
| csv::thoth | Thoth CSV |
| json::thoth | Thoth JSON |
| kbart::oclc | OCLC KBART |
| bibtex::thoth | Thoth BibTeX |
| doideposit::crossref | CrossRef DOI deposit |
| onix_2.1::proquest_ebrary | ProQuest Ebrary ONIX 2.1 |
| marc21record::thoth | Thoth MARC 21 Record |
| marc21markup::thoth | Thoth MARC 21 Markup |
| marc21xml::thoth | Thoth MARC 21 XML |
